2022 Rare Disease Day

February 28, 2022 10:00 AM - 12:30 PM

MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139

Add to Calendar 2/28/2022 10:00:00 AM 2/28/2022 12:30:00 PM 2022 Rare Disease Day MassBio recognizes Rare Disease Day by highlighting the research to treat and cure rare diseases happening in Massachusetts. The last day of February has been designated as Rare Disease Day worldwide to raise awareness about the public health issues associated with rare diseases, which affect nearly 30 million Americans and countless others around the world.

This year’s program will focus on how we can better address health inequity and racial disparities among the rare disease community. Attendees will hear an inspiring Possible Talk, an insightful panel of industry, physicians, patients/caregivers, and advocates, along with a closing patient keynote. Ample networking time will be provided (virtually, too!).

Alone we are rare, together we are strong.® (This slogan is a registered trademark of the National Organization for Rare Disorders.)

To inquire about sponsorship opportunities, contact Laura Rudberg.

Please note that this will be a hybrid event, with a limited number of in-person attendees. In-person attendance is available on a first-come, first-served basis, and all additional registrants will be placed on a waitlist. All in-person attendees are required to be fully vaccinated and masks will be required in all common areas of the event space, except while eating or drinking.  

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning. MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139
Vice President, LSD & Endo, US Rare Disease Business Unit, Takeda
Tony Frangie is Vice President and Head of Takeda’s US Lysosomal Storage Disorder & Endocrinology Franchise, which is part of the Company’s US Rare Disease Business Unit. He joined the Company (then Shire) in 2016 as Chief of Staff to the CEO, working on global initiatives across the business. He then moved into US Hematology leading Payer & Channel Strategy, prior to Takeda’s acquisition of Shire. Previously, he worked at McKinsey & Co, where he supported Shire’s R&D organization and the integrations of Dyax and Baxalta. Prior to that, Tony built his commercial experience through various roles at Hologic, OmniGuide, Genzyme, and Akzo Nobel. Tony holds an A.B. in Cell Biology from Colby College and an M.B.A. from Harvard Business School. He lives just outside of Boston with his wife, Mindy, and three children, Grace, Olivia, and Ryan.

Brought to you by